蒙医放血疗法对高脂血症模型大鼠的作用机制研究

发布时间：2018-06-19 03:22

本文选题：蒙医放血疗法 + 高脂血症模型大鼠　；参考：《北京中医药大学》2015年博士论文

【摘要】：高脂血症即血清总胆固醇、甘油三酯、低密度脂蛋白增高,高密度脂蛋白降低,脂代谢紊乱是诱发心脑血管疾病的主要隐患,严重危害着人类健康。心脑血管病被WHO确认是危害人类健康的“头号杀手",全世界每年大约有1500万人死于心脑血管疾病.而美国动脉粥样硬化性血管疾病的发病率高,是重要的致死性病因,每年约占所有死亡原因的1/3。美国成年人高脂血症发病率大约占50%。在中国心脑血管疾病病死率,从上世纪60年代居第七位,现在己上升到第一位,有高脂血症倾向者,约占人口的35%。尤其是血團总胆固醇水平升高是动脉粥样硬化(AS)的重要危险因素之一。一旦引发则易增加心脑血管疾病的发病率和死亡率,从目前发生率有年轻化趋势。预防和治疗高脂血症是近年来医学研究的热点。众多的临床研究表明放血疗法对高脂血症的治疗存在优势。本课题采用放血疗法治疗高脂血症模型大鼠,观察脂质代谢、抗氧化与内皮功能及肝组织相关指标的影响,探讨放血疗法治疗高脂血症的机制,对蒙医放血疗法治疗高脂血症的临床研究提供实验依据。该论文文献综述部分和实验部分两个部分组成。文献综述部分主要叙述了高脂血症的西医发病机理、蒙医病因分析和该病的治疗现状以及放血疗法临床应用方面。实验部分:目的:通过放血疗法治疗高脂血症模型大鼠实验研究,初步探讨蒙医放血疗法对高脂血症的作用机制,预防和治疗高脂血症及其相关疾病提供实验依据。方法:将50只wistar大鼠,体重(200士20)g以普通饲料进行适应性饲养1周,按体重随机分为5组,每组10只,分别为空白对照组(A组)、氋脂血症模型组(B组)、放血组(C组)、常规针刺组(D组)、阳性药物对照组(E组);空白对照组以普通饲料喂养,其他各组均以高脂饲料饲养。从第6周末开始,空白对照组和氋脂血症模型组大鼠断尾采血1次,检测甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇aDL"C),并计算动脉粥样硬化指数(AI)进行对比,确定造模是否成功。第7周造模成功后,空白对照组以普通饲料喂养,模型组和放血组、针刺组、阳性药物对照组以高脂饲料继续喂养,其中放血组开始放血治疗(放血前三籽汤1.8g\kg.d灌胃给药三天,每日一次;第一次在右侧脏腑总脉处放0.5ml血,第二次在左侧肝腑总脉处放0.5ml血),一周一次,共两周;针刺组每天足三里穴针剌20分钟,每天一次,两周为一疗程;阳性药物对照组每天脂必妥灌胃给药(0.42g\kg.d),空白对照组每天灌胃0.3%CMC-钠溶液。治疗结束后取材检测血清TG、TC、HDL-C、LDL-C,全血高切、低切、细胞压积、红细胞聚集指数、血i}粘度、红细胞电泳时间等指标,血清中及肝脏组织中SOD的活力、MDA的含量、GSH-Px含量、血装ET活性、血清NO、血架TXB2、6-keto-PGFl a、LPL、HL等指标;光镜下观察肝脏形态结构。结果:1.治疗结束后血脂指标方面:TG、TC、LDL-C水平:C组与模型组比较P0.01,D、E组与模型组比较P0.05,说明C、D、E组均能降低TG、TC、LDL-C水平,但C组优于D、E组;HDL-C水平:C、D、E组与模型组比较P0.05,说明C、D、E组均有升高HDL-C作用,但组间无明显差异。2.血液流变学方面:C组与模型组比较全血高切、低切、细胞压积、红细胞聚集指数、血架粘度、红细胞电泳时间均P0.01,极显著;D、E组与模型组全血高切、低切、细胞压积、红细胞聚集指数、血菜粘度、红细胞电泳时间比较均P0.05,有显著性差异。说明调节血液流变学方面放血组优于常规针刺组和脂必妥组。3.抗氧化指标方面:治疗后SOD、GSH-Px: C、D、E组与模型组比较均P0.05,有显著性差异,说明C、D、E组均有提氋SOD和GSH-Px作用;MDA:C、D、E组与模型组比较均P0.05,无显著性差异,但MDA含量标准值比模型组低,说明降低MDA的趋向。4.血管内皮功能方面:ET:与模型组比较D、E组均P0. 05,C组P0.01有显著性差异,说明降低ET活性方面C组优于D、E组。血清NO:与模型组比较C、D组均P0.05,E组P0.01有显著性差异,说明提高NO方面E组优于C、D组。5.血脂酶方面:LPL、HL含量:C、D、E组与模型组比较均P 0.05,说明C、D、E组能够升高LPL、HL含量,但组间无显著性差异。血菜中TXB2、6-Keto-PGFla影响:C、D、E组与模型组比较P0.05,无显著性差异,说明三组治疗方法对血i}中TXB2、6-Keto-PGFla的影响不明显,但从标准值上看有降低血浆中TXB2、6-Keto-PGFla的趋势。6.肝脏形态学方面:与模型组C、D、E组P0.05,有显著性差异,说明C、D、E组对肝脏均有保护作用。结论:1.蒙医放血疗法能够明显降低高脂血症血清TC、TG、LDL-C的水平,提高HDL-C水平。说明脂质代谢方面具有良性调节作用。2.蒙医放血疗法能够有效影响血液流变学相关指标,加快血流速度,防治动脉硬化及心脑血管疾病的发生。3.通过检测高脂血症血清和肝组织SOD、MDA、GSH-Px等指标,总结出蒙医放血疗法可增加抗氧化酶活性,减轻脂质过氧化。4.放血疗法对血装ET血清NO的影响,可证明放血疗法通过减轻血管内皮的损害,可以阻止高脂血症向AS及CHD的发展,这对预防和减低AS及CHD的发生具有重要意义。5.LPL是水解脂蛋白中的TG的重要酶类,HL主要在LDL-C和HDL-C代谢中起重要作用,放血疗法通过升高LPL、HL含量,能够调节血脂蛋白酶,从而达到调节脂质代谢作用。6.蒙医放血疗法对肝脏形态学的变化说明放血疗法可以改善肝脏脂肪细胞的代谢功能,保护肝脏的作用。
[Abstract]:Hyperlipidemia, such as serum total cholesterol, triglycerides, low density lipoprotein, high density lipoprotein, and lipid metabolism disorder, is the main hidden danger of cardiovascular and cerebrovascular diseases, which seriously endangers human health. Cardio cerebral vascular disease is confirmed by WHO as the "No. 1 killer", which is the first killer of human health, and about 15 million people die from heart and brain every year in the world. The incidence of atherosclerotic vascular disease in the United States is high, and it is an important cause of death. The incidence of hyperlipidemia in 1/3. American adults, which accounts for about all causes of death every year, accounts for about 50%. in the death rate of cardiovascular and cerebrovascular diseases in China. It was the seventh in the 60s of last century, and now it has risen to the first, with hyperlipidemia. It is one of the most important risk factors of atherosclerosis (AS) that the population of 35%., especially the increase of total cholesterol in the blood group, is one of the most important risk factors for atherosclerosis (AS). The study shows that blood letting therapy has advantages in the treatment of hyperlipidemia. This subject uses blood letting therapy to treat hyperlipidemia model rats, observe the effect of lipid metabolism, anti oxidation and endothelial function and liver tissue, explore the mechanism of hyperlipidemia treatment with blood letting therapy, and study the clinical study on hyperlipidemia treated by Mongolian medicine bleeding therapy. This paper provides an experimental basis. The literature review and experimental part are made up of two parts. The literature review mainly describes the pathogenesis of hyperlipidemia in western medicine, the analysis of the etiology of Mongolian medicine and the status of the treatment of the disease and the clinical application of the blood letting therapy. A preliminary study on the mechanism of hyperlipidemia, prevention and treatment of hyperlipidemia and its related diseases by Mongolian medicine bleed therapy. Methods: 50 Wistar rats, body weight (200, 20) g were adapted for 1 weeks with normal diet, and they were randomly divided into 5 groups according to body weight, 10 in each group (group A), respectively. The disease model group (group B), the blood group (group C), the routine acupuncture group (group D) and the positive drug control group (group E); the blank control group was fed with ordinary feed and the other groups were fed with high fat feed. From the sixth weekend, the blank control group and the rat model group were collected for 1 times, the triglyceride (TG), the total cholesterol (TC) and the high density lipoprotein were detected. Cholesterol (HDL-C), low density lipoprotein cholesterol aDL "C" and calculated the atherosclerotic index (AI) compared to determine whether the model was successful. After seventh weeks of success, the blank control group was fed with ordinary diet, the model group and the blood group, the acupuncture group, the positive drug control group continued to feed with high fat diet, of which the blood group began to release blood. The treatment (three seed soup before bleeding) was given to the three seed soup for three days, once a day; the first time to put 0.5ml blood in the right viscera general vein, and the second time to put 0.5ml blood in the total vein of the left liver Zang Fu, once a week for two weeks; the acupuncture group was punctured for 20 minutes every day at Zusanli, once a day and two weeks as a course of treatment; the positive drug control group was given the medicine every day. ( 0.42gkg.d), the blank control group was filled with 0.3%CMC- sodium solution every day. After the treatment, the blood serum TG, TC, HDL-C, LDL-C, whole blood high cutting, low cutting, hematocrit, erythrocyte aggregation index, blood i} viscosity, erythrocyte electrophoresis time and other indexes, the activity of SOD in serum and liver tissue, MDA content, GSH-Px content, ET blood activity, serum NO, blood TXB2,6-keto-PGFl a, LPL, HL and so on; observe the morphological structure of the liver under light microscope. Results: 1. after the end of the treatment, the blood lipid index: TG, TC, LDL-C level: C group and model group are compared with P0.01, D, E group and model group. The results showed that C, D and E groups increased the effect of HDL-C, but there was no significant difference in.2. blood rheology between groups: C group and model group compared full blood, low cut, cell pressure, erythrocyte aggregation index, blood frame viscosity, erythrocyte electrophoresis time P0.01, very significant; D, E group and model group all blood high cut, low cut, cell pressure product, erythrocyte aggregation index, blood vegetable sticky Degree, erythrocyte electrophoresis time compared with P0.05, there are significant differences. It shows that the regulation of Hemorheology in the blood group is better than the conventional acupuncture group and the.3. antioxidant index in the lipbally group: after the treatment, SOD, GSH-Px: C, D, E group are all P0.05, and there are significant differences between the group and the model group. The model group was all P0.05, but there was no significant difference, but the standard value of MDA content was lower than that of the model group. It showed that the tendency of reducing MDA was.4. vascular endothelial function: ET: was compared with model group D, E group was P0. 05, C group P0.01 had significant difference, which showed that C group in the aspect of reducing ET activity was better than that of model group. There was no significant difference between the group E and the model group. There was no significant difference between the group and the model group. There were no significant differences between the group and the model group. There was no significant difference between the group and the model group, which showed that there were three groups of treatment methods for blood NO. } the effect of TXB2,6-Keto-PGFla is not obvious, but from the standard value, there is a tendency to reduce the trend of TXB2,6-Keto-PGFla in the plasma.6. liver morphology: with the model group C, D, E group P0.05, there are significant differences, indicating that C, D, E group have protective effects on the liver. Conclusion: 1. Mongolian medicine therapy can obviously reduce the serum TC, TG, and water of hyperlipidemia. Level, improve the level of HDL-C. It shows that lipid metabolism has a benign regulation effect,.2. Mongolian medicine blood letting therapy can effectively affect blood rheology related indexes, speed up blood flow speed, prevent arteriosclerosis and cardio cerebral vascular diseases,.3. through detecting SOD, MDA, GSH-Px and other indexes of hyperlipidemia serum and liver tissue, sum up the Mongolian medicine bleeding therapy. The method can increase the activity of antioxidant enzymes and reduce the effect of lipid peroxidation.4. bleeding therapy on the serum NO of blood loaded ET. It is proved that blood letting therapy can prevent the development of hyperlipidemia to AS and CHD by reducing the damage of vascular endothelium, which is important to prevent and reduce the occurrence of AS and CHD.5.LPL is an important enzyme of TG in the hydrolytic lipoprotein. HL plays an important role in the metabolism of LDL-C and HDL-C. Blood letting therapy can regulate lipid protease by increasing LPL, HL content and regulating blood lipid protease, thus it can regulate the changes of liver morphology by regulating the lipid metabolism effect of.6. Mongolian medicine. It shows that blood therapy can improve the metabolic function of liver fat cells and protect the liver.
【学位授予单位】：北京中医药大学
【学位级别】：博士
【学位授予年份】：2015
【分类号】：R29;R-332

【参考文献】